We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-5.96%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.19B
AUM Growth
-$667M
Cap. Flow
-$151M
Cap. Flow %
-3.6%
Top 10 Hldgs %
47.69%
Holding
131
New
13
Increased
16
Reduced
22
Closed
21

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$101M
2
SION
Sionna Therapeutics
SION
+$60.5M
3
AXSM icon
Axsome Therapeutics
AXSM
+$44.1M
4
APLS
Apellis Pharmaceuticals
APLS
+$39.6M
5
UNH icon
UnitedHealth
UNH
+$35.9M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$117M
2
MRK icon
Merck
MRK
+$82.6M
3
BIIB icon
Biogen
BIIB
+$77.9M
4
ISRG icon
Intuitive Surgical
ISRG
+$61.2M
5
UHS icon
Universal Health Services
UHS
+$48.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NSPR icon
76
InspireMD
NSPR
$32.1M
$5.74M 0.14%
2,133,405
– –
SRRK icon
77
Scholar Rock
SRRK
$5.92B
$4.88M 0.12%
151,800
– –
FBRX icon
78
Forte Biosciences
FBRX
$1.57B
$4.6M 0.11%
593,088
-6,912
-1% -$81.6K
IMA
79
ImageneBio Inc
IMA
$65.5M
$4.53M 0.11%
294,947
– –
KRYS icon
80
Krystal Biotech
KRYS
$10.7B
$4.24M 0.1%
23,500
– –
ENGN icon
81
enGene Therapeutics
ENGN
$118M
$3.99M 0.1%
891,616
-28,723
-3% -$178K
ORIC icon
82
Oric Pharmaceuticals
ORIC
$1.23B
$3.91M 0.09%
+700,000
New +$6.12M
BCAX
83
Bicara Therapeutics
BCAX
$1.77B
$3.89M 0.09%
298,301
– –
QTTB icon
84
Q32 Bio
QTTB
$467M
$3.72M 0.09%
2,252,987
– –
BIOA
85
BioAge Labs
BIOA
$974M
$3.47M 0.08%
921,959
– –
RPTX
86
DELISTED
Repare Therapeutics
RPTX
$3.28M 0.08%
3,322,488
– –
GPCR icon
87
CALL
Structure Therapeutics
GPCR
$3.4B
$2.6M 0.06%
150,000
– –
PASG icon
88
Passage Bio
PASG
$14.7M
$2.48M 0.06%
351,731
-18,512
-5% -$200K
INSM icon
89
Insmed
INSM
$22.6B
$2.19M 0.05%
28,659
-65,900
-70% -$5.04M
CBLL
90
CeriBell Inc
CBLL
$677M
$2.16M 0.05%
112,500
– –
TIL icon
91
Instil Bio
TIL
$49.4M
$2.03M 0.05%
116,785
– –
CMMB
92
Chemomab Therapeutics
CMMB
$10.5M
$1.9M 0.05%
435,318
– –
CRDF icon
93
Cardiff Oncology
CRDF
$63.6M
$1.8M 0.04%
573,884
-964,578
-63% -$3.81M
XFOR icon
94
X4 Pharmaceuticals
XFOR
$371M
$1.6M 0.04%
225,884
-11,900
-5% -$164K
NKTX icon
95
Nkarta
NKTX
$159M
$1.51M 0.04%
821,400
– –
TRAW icon
96
Traws Pharma
TRAW
$7.81M
$1.39M 0.03%
605,531
– –
FATE icon
97
Fate Therapeutics
FATE
$270M
$1.33M 0.03%
1,680,580
– –
TSBX
98
DELISTED
Turnstone Biologics
TSBX
$1.27M 0.03%
3,099,265
– –
AMLX icon
99
Amylyx Pharmaceuticals
AMLX
$2.17B
$1.23M 0.03%
348,000
– –
PHGE icon
100
BiomX
PHGE
$1.98M
$993K 0.02%
94,093
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2025 Portfolio in Review

As of Q1 2025, OrbiMed held 131 positions worth $4.19B, down 14% from $4.86B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

OrbiMed withdrew a net $151M in Q1 2025, closing 21 positions and reducing 22 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $117M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier.

Against the trend, OrbiMed opened a new position in Pfizer worth $97.6M.

  • OrbiMed's largest Q1 2025 buy was Pfizer: 3,850,200 shares worth $97.6M.
  • OrbiMed added most to UnitedHealth in Q1 2025, an estimated $35.9M increase.
  • OrbiMed's biggest Q1 2025 reduction was Intuitive Surgical, cutting an estimated $61.2M.
  • OrbiMed fully exited Sarepta Therapeutics in Q1 2025, selling an estimated $117M.
  • OrbiMed's ten largest holdings make up 48% of its $4.19B portfolio in Q1 2025.
  • OrbiMed opened 13 new positions and closed 21 in Q1 2025.
  • OrbiMed's portfolio value fell 14% quarter-over-quarter to $4.19B.

Based on OrbiMed's 13F filing for Q1 2025, filed 15 May 2025.